Navigation Links
Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
Date:12/3/2007

PALO ALTO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced it will report data from the Phase 1 dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets at the 49th annual meeting of the American Society of Hematology. The presentation is scheduled for Saturday, December 8, 2007, from 5:30 to 7:30 pm in Hall B3 and B4 at the Georgia World Congress Center in Atlanta. The presentation (Abstract # 1454, Board # 608) is titled: "Phase 1 Dose Escalation Study of TLK199 Tablets (TELINTRA), a Novel Glutathione Analog, in Myelodysplastic Syndrome." It will be presented during the poster session "Myelodysplastic Syndromes: Clinical Studies, Including Transplantation."

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidates are TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA(R), which is in development for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 Quantum Radiology,s Mobile Breast ... radiologist interpretation directly to women at the workplace, thereby ... such as Delta Air Lines and SunTrust Bank, and ... a component of wellness initiatives. "I think ... It enables them to have a mammogram without taking ...
(Date:12/2/2016)... , Dec. 2, 2016  Eli Lilly and Company ... guidance for 2017 and provide updated financial guidance for ... conduct a conference call on that day with the ... financial guidance. The conference call will begin ... public can access a live webcast of the conference ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic ... & Support) is Expected to Gain a Significant Market Share ... Orthopedic Ailments  ... , According to a ... on Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected ...
Breaking Medicine Technology:
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... NJ (PRWEB) , ... December 02, 2016 , ... Sourced ... Water has some unique properties including its unmatched natural purity of just 6 ppm ... clean and crisp. , Nothing Water has been available in several ShopRite and FoodTown ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard Process, ... an annual ranking and recognition of the largest closely held companies headquartered in ... from 2008-2016. In addition, Standard Process was awarded the Talent Award for providing ...
Breaking Medicine News(10 mins):